FDA clears GE's PET/CT quantitative imaging technology

Justine Varieur Cadet | | Health Imaging | Screening
GE Healthcare has received FDA clearance of Q.Freeze, a PET/CT quantitative imaging technology designed for treatment evaluation earlier in a patient’s cancer treatment.

Q.Freeze combines the quantitative benefits of 4D phase-matched PET/CT imaging, MotionMatch, into one static image, according to the Waukesha, Wis.-based company. Q.Freeze is included in GE Healthcare's Q.Suite, a collection of features designed to provide consistent standardized uptake value (SUV) readings, and which does not have CE Mark approval.

Justine Varieur Cadet

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.